SOURCE: Medistem Laboratories, Inc.

February 28, 2008 08:05 ET

Medistem to Present at Stem Cell Partnering Conference

Company to Discuss Advances on Menstrual ERC Stem Cell Program

SCOTTSDALE, AZ--(Marketwire - February 28, 2008) - Medistem Laboratories, Inc. (OTCBB: MDSM) (FRANKFURT: S2U), announced today it will be presenting recent data from its ongoing ERC programs at the inaugural Stem Cell Partnering Series Conference on February 29th in La Jolla, California.

"We are pleased Medistem was invited to speak at this important event. Norman Palmer, Founder and CEO of Stem Cell Partner Series, has done a fantastic job of assembling an internationally renowned group of scientific and corporate leaders dedicated to acceleration of stem cell commercialization," said Chris McGuinn, COO of Medistem.

Medistem is currently developing cellular therapies for peripheral artery disease based on the endometrial regenerative cell (ERC), a stem cell population isolated from menstrual blood that can be used as a "universal donor." A recent scientific publication on this cell type can be accessed freely at

"Therapeutics development can not be performed in isolation. Medistem looks forward to interacting with stem cell colleagues from companies such as StemCells Inc, Novocell, Aldagen, Cytori, Aastrom, Tissue Regeneration Therapeutics, Lonza, Invitrogen, Regentech, Aggregate Therapeutics, Progenitor Cell Therapy, California Stem Cell Inc and National Stem Cell Inc," said Thomas Ichim, Medistem's Chief of Scientific Development. He continued, "Since the industry is so young, it is important for all stakeholders to strategically work together at overcoming current hurdles of stem cell commercialization."

About Medistem Laboratories

Medistem Laboratories is a biotechnology company founded to develop and commercialize technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product is a "universal donor" stem cell derived from the menstrual blood that possesses the ability to differentiate into all major tissue types of the body, produce high amounts of growth factors, and has astonishing replicative ability. Due to Medistem's relationships and collaborative efforts with respected institutions, Medistem believes it is well positioned to be a leading developer of adult stem cell products.

Cautionary Statement

This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include projections of matters that affect revenue, the ability to develop or license certain technologies and receive associated licensing fees; operating expenses or net earnings; projections of capital expenditures; projections of growth; hiring plans; plans for future operations; financing needs or plans; plans relating to the company's products and services; and assumptions relating to the foregoing.

Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.

Some of the important factors that could cause the company's actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: the company's ability to anticipate future license fees, technology development limitations, intense competition, risk of business interruption, management of rapid growth, need for additional financing, regulatory approvals and requirements, dependence on key personnel and research, management and other administrative costs.

These factors are discussed in greater detail in the company's quarterly and annual periodic reports, all as filed with the Securities and Exchange Commission.

Contact Information